1. Home
  2. GNPX vs HSDT Comparison

GNPX vs HSDT Comparison

Compare GNPX & HSDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNPX
  • HSDT
  • Stock Information
  • Founded
  • GNPX 2009
  • HSDT N/A
  • Country
  • GNPX United States
  • HSDT United States
  • Employees
  • GNPX N/A
  • HSDT N/A
  • Industry
  • GNPX Biotechnology: Pharmaceutical Preparations
  • HSDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • GNPX Health Care
  • HSDT Health Care
  • Exchange
  • GNPX Nasdaq
  • HSDT Nasdaq
  • Market Cap
  • GNPX 5.5M
  • HSDT 6.4M
  • IPO Year
  • GNPX 2018
  • HSDT N/A
  • Fundamental
  • Price
  • GNPX $0.31
  • HSDT $7.59
  • Analyst Decision
  • GNPX
  • HSDT Hold
  • Analyst Count
  • GNPX 0
  • HSDT 1
  • Target Price
  • GNPX N/A
  • HSDT N/A
  • AVG Volume (30 Days)
  • GNPX 23.7M
  • HSDT 30.9K
  • Earning Date
  • GNPX 08-14-2025
  • HSDT 11-11-2025
  • Dividend Yield
  • GNPX N/A
  • HSDT N/A
  • EPS Growth
  • GNPX N/A
  • HSDT N/A
  • EPS
  • GNPX N/A
  • HSDT N/A
  • Revenue
  • GNPX N/A
  • HSDT $295,000.00
  • Revenue This Year
  • GNPX N/A
  • HSDT N/A
  • Revenue Next Year
  • GNPX N/A
  • HSDT $75.13
  • P/E Ratio
  • GNPX N/A
  • HSDT N/A
  • Revenue Growth
  • GNPX N/A
  • HSDT N/A
  • 52 Week Low
  • GNPX $0.14
  • HSDT $5.37
  • 52 Week High
  • GNPX $3.97
  • HSDT $1,200.00
  • Technical
  • Relative Strength Index (RSI)
  • GNPX 69.58
  • HSDT 46.25
  • Support Level
  • GNPX $0.20
  • HSDT $5.78
  • Resistance Level
  • GNPX $0.40
  • HSDT $6.11
  • Average True Range (ATR)
  • GNPX 0.04
  • HSDT 0.44
  • MACD
  • GNPX 0.02
  • HSDT 0.76
  • Stochastic Oscillator
  • GNPX 61.56
  • HSDT 56.37

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

About HSDT Helius Medical Technologies Inc. (DE)

Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS) is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.

Share on Social Networks: